Testing an Injectable Treatment for Eye Inflammation in Adults

Plain-English translation of NCT07663331 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This trial is testing Tebiovio® (Adalimumab), an injectable medication that helps calm down inflammation inside the eye. The study will enroll 30 adults with a specific type of eye inflammation called non-infectious uveitis that hasn't improved enough with steroid medications alone. Researchers want to see how safe and effective this medication is at controlling the inflammation and improving vision.

Some patients with eye inflammation don't get enough relief from steroid pills, even at high doses, and need additional treatment options. This medication works differently than steroids and may help people whose eye inflammation is hard to control.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with active non-infectious inflammation inside the eye (intermediate, posterior, or panuveitis)
you have been taking oral steroid medication (prednisone or equivalent) at a dose of 10–60 mg per day for at least 2 weeks before screening
you are willing and able to use effective birth control throughout the trial and for 6 months after it ends
you have received a recommendation from your doctor to try this medication after discussing the risks and benefits with them

You likely don't qualify if…

you have inflammation only in the front of the eye (anterior uveitis)
you have or are suspected to have an infection causing the eye inflammation
you have had eye surgery within the past 90 days (with some exceptions)
you have certain other eye conditions such as severe cataracts, very high eye pressure despite treatment, or severe vision loss
you have a current or past history of demyelinating diseases such as multiple sclerosis

What participation looks like

If you enroll, you will receive an initial injection of 80 mg of the medication, then 40 mg injections every 2 weeks starting 1 week after your first dose. You will be monitored to see how well the medication controls your eye inflammation and to watch for any side effects. The study will track your progress over 24 weeks to see if the treatment works and is safe for you.

AI-generated summary from trial data · Aug 3, 2026 · Not medical advice

Trial locations(1 site)

China

Tianjin Medical University Eye Hospital, Tianjin, Tianjin Municipality